» Articles » PMID: 36428669

The Anti-Vascular Endothelial Growth Factor Receptor 1 (VEGFR-1) D16F7 Monoclonal Antibody Inhibits Melanoma Adhesion to Soluble VEGFR-1 and Tissue Invasion in Response to Placenta Growth Factor

Overview
Journal Cancers (Basel)
Publisher MDPI
Specialty Oncology
Date 2022 Nov 26
PMID 36428669
Authors
Affiliations
Soon will be listed here.
Abstract

Placenta growth factor (PlGF) is a member of the vascular endothelial growth factor (VEGF) family involved in tumor-associated angiogenesis and melanoma invasion of the extra-cellular matrix (ECM) through activation of membrane VEGF receptor 1 (VEGFR-1). A soluble VEGFR-1 (sVEGFR-1) form is released in the ECM, where it sequesters proangiogenic factors and stimulates endothelial or tumor cell adhesion and chemotaxis through interaction with α5β1 integrin. The anti-VEGFR-1 monoclonal antibody (D16F7 mAb) inhibits VEGF-A or PlGF-mediated signal transduction without affecting ligand interaction, thus preserving sVEGFR-1 decoy function. The aim of this study was to investigate whether D16F7 mAb hampers melanoma spread by in vitro analysis of cell adhesion to sVEGFR-1, ECM invasion, transmigration through an endothelial cell monolayer and in vivo evaluation of tumor infiltrative potential in a syngeneic murine model. Results indicate that D16F7 mAb significantly inhibits melanoma adhesion to sVEGFR-1 and ECM invasion, as well as transmigration in response to PlGF. Moreover, treatment of melanoma-bearing mice with the anti-VEGFR-1 mAb not only inhibits tumor growth but also induces a significant reduction in bone infiltration associated with a decrease in PlGF-positive melanoma cells. Furthermore, D16F7 mAb reduces PlGF production by melanoma cells. Therefore, blockade of PLGF/VEGFR-1 signaling represents a suitable strategy to counteract the metastatic potential of melanoma.

Citing Articles

Relevance of the GH-VEGFB/VEGFA axis in liver grafts from brain-dead donors with alcohol-associated liver disease.

Mico-Carnero M, Rojano-Alfonso C, Maroto-Serrat C, Cutrin J, Casillas-Ramirez A, Peralta C Front Cell Dev Biol. 2025; 12():1455258.

PMID: 39839674 PMC: 11747040. DOI: 10.3389/fcell.2024.1455258.


Prognostic Value of PlGF Upregulation in Prostate Cancer.

Scimeca M, Giacobbi E, Servadei F, Palumbo V, Palumbo C, Finazzi-Agro E Biomedicines. 2024; 12(10).

PMID: 39457506 PMC: 11505493. DOI: 10.3390/biomedicines12102194.


Angiogenesis Still Plays a Crucial Role in Human Melanoma Progression.

Cazzato G, Ingravallo G, Ribatti D Cancers (Basel). 2024; 16(10).

PMID: 38791873 PMC: 11120419. DOI: 10.3390/cancers16101794.


Programmed Cell Death Pathways in Cholangiocarcinoma: Opportunities for Targeted Therapy.

Scimeca M, Rovella V, Palumbo V, Scioli M, Bonfiglio R, Tor Centre Cancers (Basel). 2023; 15(14).

PMID: 37509299 PMC: 10377326. DOI: 10.3390/cancers15143638.


Biomolecules Involved in Both Metastasis and Placenta Accreta Spectrum-Does the Common Pathophysiological Pathway Exist?.

Rekowska A, Obuchowska K, Bartosik M, Kimber-Trojnar Z, Slodzinska M, Wierzchowska-Opoka M Cancers (Basel). 2023; 15(9).

PMID: 37174083 PMC: 10177254. DOI: 10.3390/cancers15092618.

References
1.
Atzori M, Tentori L, Ruffini F, Ceci C, Bonanno E, Scimeca M . The Anti-Vascular Endothelial Growth Factor Receptor-1 Monoclonal Antibody D16F7 Inhibits Glioma Growth and Angiogenesis In Vivo. J Pharmacol Exp Ther. 2017; 364(1):77-86. DOI: 10.1124/jpet.117.244434. View

2.
Failla C, Carbo M, Morea V . Positive and Negative Regulation of Angiogenesis by Soluble Vascular Endothelial Growth Factor Receptor-1. Int J Mol Sci. 2018; 19(5). PMC: 5983705. DOI: 10.3390/ijms19051306. View

3.
Zekri J, Marples M, Taylor D, Kandukurti K, McParland L, Brown J . Complications of bone metastases from malignant melanoma. J Bone Oncol. 2017; 8:13-17. PMC: 5568878. DOI: 10.1016/j.jbo.2017.08.003. View

4.
Orecchia A, Mettouchi A, Uva P, Simon G, Arcelli D, Avitabile S . Endothelial cell adhesion to soluble vascular endothelial growth factor receptor-1 triggers a cell dynamic and angiogenic phenotype. FASEB J. 2013; 28(2):692-704. DOI: 10.1096/fj.12-225771. View

5.
Lassen U, Nielsen D, Sorensen M, Winstedt L, Niskanen T, Stenberg Y . A phase I, dose-escalation study of TB-403, a monoclonal antibody directed against PlGF, in patients with advanced solid tumours. Br J Cancer. 2012; 106(4):678-84. PMC: 3322959. DOI: 10.1038/bjc.2011.609. View